Acadia Pharmaceuticals: Remlifanserin Is In Trouble

Summary Acadia Pharmaceuticals (ACAD) reported phase 2/3 results for remlifanserin in Alzheimer’s disease psychosis, with the high dose missing statistical significance but showing positive efficacy trends. Remlifanserin’s safety profile was clean, but the effect size on the primary endpoint was low, raising concerns about clinical utility and replicability in phase 3. I am now even less optimistic about remlifanserin’s phase 3 success, lowering my probability of success to 25% due to efficacy and trial design concerns. ACAD’s valuation remains supported by Nuplazid and Daybue, with the pipeline offering long-term upside optionality regardless of remlifanserin’s outcome. I do much more than just articles at Growth Stock Forum: Members get access to model portfolios, regular updates, a chat room, and more. Learn More » s-cphoto/iStock via Getty Images Acadia Pharmaceuticals ( ACAD ) reported topline results from part 2 of the phase 2/3 trial of remlifanserin in patients with Alzheimer’s disease psychosis (‘ADP’). The high dose missed statistical significance but showed positive efficacy trends, and This article was written by ONeil Trader 9.66K Followers Follow ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential.He leads the investing group Growth Stock Forum which features: a model portfolio of 12-15 names updated regularly, a Top Picks list of up to 10 stocks that are expected to perform well in the current calendar year, Momentum Ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.